In total, 1,177 participants were enrolled with R0 resected NSCLC, stage IB-IIIA (according to TNM 7), ECOG 0-1 performance status, any verified PD-L1 expression level, and known EGFR and ALK alterations was not a requirement for inclusion. This evidence concerns the gene ALK and non-small cell lung carcinoma.